TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) just unveiled an update.
Shanghai Henlius Biotech, Inc. has initiated an international multi-center phase 1 clinical trial for HLX17, a biosimilar of pembrolizumab, in patients with multiple resected solid tumors in mainland China. This trial aims to evaluate the pharmacokinetic profile, efficacy, safety, and immunogenicity of HLX17 compared to KEYTRUDA, with plans to expand the trial to the United States, Europe, and Australia. The announcement marks a significant step in the company’s efforts to position itself in the global oncology market, leveraging the high global sales of pembrolizumab, which reached approximately USD 32.056 billion in 2024.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$97.75 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. operates in the biotechnology industry, focusing on the development of biosimilar products. The company is known for its work on monoclonal antibodies, with a market focus on creating treatments for various cancers.
Average Trading Volume: 1,447,072
Technical Sentiment Signal: Buy
Current Market Cap: HK$39.92B
Find detailed analytics on 2696 stock on TipRanks’ Stock Analysis page.